We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Review · April 20, 2021

Cardiovascular Protection With SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease

Hypertension

 

Additional Info

Hypertension
Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved
Hypertension 2021 Mar 29;[EPub Ahead of Print], P Sarafidis, CE Papadopoulos, V Kamperidis, G Giannakoulas, M Doumas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading